Regenerative Therapy

The New York Stem Cell Summit Issued an  ”Adult Stem Cell Fact Sheet” which provides extensive information on clinical applications and companies in the US.
http://clients.criticalimpact.com/user/24825/files/StemCell_Fact_Sheet2012.pdf
http://www.stemcellsummit.com/

Israel Stem Cells & Regenerative Medicine Progress
August 2011 update
Israeli companies continue to lead in developing cell based therapeutic products. Three companies are already in clinical studies and few others are progressing rapidly to this stage.
 Gamida-Cell is presently in late stages of phase III study, testing StemEx, its ex vivo expanded cord blood derived hematopoietic stem cells for treatment of hematological malignancies. Pluristem has also reached phase III, testing PLX-PAD, its placenta derived mesenchymal stromal cells …

A short fascinating talk on how to improve your treatment by using patient’s networks. 
Dave deBronkart found by himself the medical treatment that saved his life. Now he calls on all patients to talk with one another, know their own health data, and make health care better one e-Patient at a time.
http://www.ted.com/talks/dave_debronkart_meet_e_patient_dave.html?utm_so
Source: TEd.com and http://epatientdave.com/

The future of medicine is happening now - 15 min – worth watching!
“Dr. Daniel Kraft: Medicine’s future? There’s an app for that”
http://www.ted.com/talks/daniel_kraft_medicine_s_future.html
Source: TED.com

Cell therapy medical tourism: Time for action
A white paper guidelines and position on medical tourism was published by the International Society for Cell Therapy.
Source: Kurt C. Gunter et al. Cytotherapy  2010; 12: 965–968 
 
http://www.celltherapysociety.org/uploads/files/Telegraft/2011/february/CT%20Medical%20Tourism%20ISCT%20WP.pdf
 

Educational book on stem cell science
A new book is available for Introduction to Stem Cell Science, designed to help non-scientists understand some of the fundamental and technical aspects of stem cells, stem cell research and how these cells are used now and may be used in the future to help improve human health. There are consumer edition, classroom edition and teacher edition. Published by The Genetics Policy Institute (GPI) and available for sale: http://www.worldstemcellsummit.com/book

Multiple Sclerosis (MS)
Stem Cells Treatments Review
 Keren Shternhall-Ron Ph.D.
 Multiple Sclerosis is a chronic neurological disorder that affects the central nervous system (brain and spinal cord). MS is considered an autoimmune disease in which the myelin sheaths are damaged and destroyed by the immune system. Moreover, the inflammatory reaction can result in permanent loss of function and damage to the Oligodendrocytes (the cells that produce myelin). As a result, the brain is limited in its ability to …

Comprehensive article on regenerative medicine industry
An updated and informative review on current regen industry and therapies.
“Regenerative medicine cell therapies: numbers of units manufactured and patients treated between 1988 and 2010″
Chris Mason‌† and Elisa Manzotti‌
Regenerative Medicine
May 2010, Vol. 5, No. 3, Pages 307-313
http://www.futuremedicine.com/doi/full/10.2217/rme.10.37
Reference by Abner Mhashilkar, Ph.D.

A new book is available for Introduction to Stem Cell Science, designed to help non-scientists understand some of the fundamental and technical aspects of stem cells, stem cell research and how these cells are used now and may be used in the future to help improve human health. There are consumer edition, classroom edition and teacher edition. Published by The Genetics Policy Institute (GPI) and available for sale: http://www.worldstemcellsummit.com/book

If you want to evaluate the potential of a new therapy, the most important parameter is how close it is to clinical utilization.
 New therapies using stem cells and regenerative approaches are constantly emerging. The amount of information in the media, both professional and popular, is huge. Nonetheless, most of it, although interesting and supportive for further development, is not applicable for present patient’s needs. If you want to evaluate the current potential of a new …